Plant-Based Biotech Enveda Therapeutics Pushes Forward in Inflammatory Skin Disease Treatment
Enveda Biosciences, a clinical-stage biotech innovator using AI and natural compounds, has announced promising Phase 1 trial results for its lead oral anti-inflammatory candidate, ENVD-101. The company is now initiating a Phase 1b study in patients with atopic dermatitis—a common chronic skin condition affecting millions globally.
What’s New?
ENVD-101, derived from plant-based compounds, has demonstrated excellent safety and tolerability in healthy volunteers. The new Phase 1b trial will evaluate the drug’s efficacy in reducing symptoms like inflammation, itching, and skin lesions in real patients with atopic dermatitis.
“We’re one step closer to changing the way inflammatory skin conditions are treated—with an oral drug inspired by nature,” said Viswa Colluru, CEO of Enveda.
The company is also running parallel trials for ulcerative colitis, suggesting ENVD-101 may have multi-condition potential in immune and inflammatory diseases.
Why It Matters:
- Atopic dermatitis affects over 15-20% of children and 10% of adults globally.
- Current therapies often rely on topical steroids or injectables.
- ENVD-101 may offer a convenient oral alternative with fewer side effects.
Tech-Driven Discovery:
Enveda leverages AI platforms to decode plant biology and rapidly identify novel therapeutic candidates. This approach has garnered attention across the biotech and digital health ecosystems for its scalability and speed.
🔗 Source: BioSpace Press Release
